TTrialPathMatch Me to Trials
← Back to trials
RecruitingElevated Lp(a)Atherosclerotic Cardiovascular Disease (ASCVD)

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

Eligible age

18+ yrs

Accepts

All genders

Locations

33 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the efficacy of muvalaplin in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke.

Sponsor: Eli Lilly and Company

You may qualify if…

  • Have Lp(a) ≥175 nanomoles per liter (nmol/L)
  • Meet one of the following criteria:
  • Have had a prior atherosclerotic cardiovascular disease (ASCVD) event (such as heart attack, stroke, or procedure to restore blood flow to the heart or other parts of the body) within 10 years prior to screening
  • Are at risk for a first ASCVD event, defined as one or more of the following:
  • Documented coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without a history of ASCVD event
  • A high coronary artery calcium (CAC) score
  • Reduced kidney function with diabetes
  • Combination(s) of high risk factors

You may not qualify if…

  • Have experienced a major cardiovascular event or surgery, such as heart attack, stroke, or procedure to restore blood flow to the heart or other parts of the body, within 90 days prior to screening or occurring between screening and randomization
  • Are planning or expected to undergo a procedure to restore blood flow in the arteries or a major heart surgery during the study
  • Have uncontrolled high blood pressure
  • Have New York Heart Association (NYHA) class III or IV heart failure
  • Have undergone a procedure to remove cholesterol from the blood within 90 days of screening, or have a planned procedure during the study
  • Have severe kidney impairment
  • Have had cancer within 5 years prior to screening

Where it's recruiting

Arizona

Apache Junction · Gilbert · Phoenix · Sun City West

California

Beverly Hills · Concord · Escondido · Fountain Valley

Colorado

Aurora · Colorado Springs · Golden

Connecticut

Stamford · Waterbury

Florida

Boca Raton · Cutler Bay · Daytona Beach · Hollywood

Georgia

Augusta · Gainesville · Woodstock

Idaho

Blackfoot · Meridian · Rexburg

Illinois

Chicago · Gurnee · Lombard · Niles

Indiana

Bloomington · Indianapolis

Kansas

Topeka

Kentucky

Covington

Louisiana

New Orleans

Source: ClinicalTrials.gov · NCT07157774 · last updated 2026-08-07

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in A · TrialPath